Epidemiology of congenital cerebral anomalies in Europe – a multi-centre, population-based EUROCAT study

**Joan K Morris1**, **Diana Wellesley2, Ingeborg Barisic3**, **Marie-Claude Addor4**, **Jorieke EH Bergman5 , Paula Braz6, Clara Cavero-Carbonell7,** **Elizabeth S Draper8, Miriam Gatt9**, **Martin Haeusler10**, **Kari Klungsoyr11**, **Jennifer J Kurinczuk12**, **Nathalie Lelong13**, **Karen Luyt14 , Catherine Lynch15**,**Mary T O’Mahony16**, **Olatz Mokoroa17**,**Vera Nelen18**, **Amanda J Neville19**, **Anna Pierini20**, **Hanitra Randrianaivo21, Judith Rankin22**, **Anke Rissmann23 , Florence Rouget 24**, **Bruno Schaub25**, **David Tucker26**, **Christine Verellen-Dumoulin27,** **Awi Wiesel28**, **Natalia Zymak-Zakutnia29,** **Monica Lanzoni30,** **Ester Garne31**

Corresponding Author: Professor Joan K Morris,

Address: Population Health Research Institute

St George’s, University of London,

Cranmer Terrace SW17 0RE UK.

Email : jmorris@sgul.ac.uk

Phone : +44(0)2087251324

*1* Population Health Research Institute, St George’s, University of London, London, *UK.*

*2University Hospitals Southampton, Faculty of Medicine and Wessex Clinical Genetics Service, Southampton, UK.*

*3Children's Hospital Zagreb, Centre of Excellence for Reproductive and Regenerative Medicine, Medical School University of Zagreb, Zagreb, Croatia.*

*4Department of Woman-Mother-Child, University Hospital Center CHUV, Lausanne, Switzerland.*

*5Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.*

*6Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.*

*7Rare Diseases Research Unit, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, Valencia, Spain.*

*8Department of Health Sciences, University of Leicester, Leicester, UK.*

*9Directorate for Health Information and Research, Valetta, Malta.*

10*Medical University of Graz, Graz, Austria.*

*11Division for mental and physical health, Norwegian Institute of Public Health, Bergen, Norway and Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.*

*12Congenital Anomaly Register for Oxfordshire, Berkshire and Buckinghamshire, National Perinatal Epidemiology Unit, University of Oxford, Oxford, UK.*

*13Paris Registry of Congenital Anomalies, Inserm UMR 1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team (Epopé), Center for Epidemiology and Statistics Sorbonne Paris Cité, Paris Descartes University, Paris, France.*

*14South West Congenital Anomaly Register, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.*

*15Department of Public Health, Health Service Executive - Kilkenny, Kilkenny, Ireland.*

*16Department of Public Health, Health Service Executive - South, Cork, Ireland.*

*17Public Health Division of, Biodonostia Research Institute, San Sebastián, Spain.*

*18Provinciaal Instituut voor Hygiene (PIH), Antwerp, Belgium.*

*19IMER Registry (Emilia Romagna Registry of Birth Defects), University of Ferrara and Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy.*

*20Tuscany Registry of Congenital Defects, CNR Institute of Clinical Physiology/Fondazione Toscana “Gabriele Monasterio”, Pisa, Italy.*

*21Registre des Malformations Congenitales de la Reunion, St Pierre, Ile de la Reunion,France.*

22*Institute of Health & Society, Newcastle University, Newcastle, UK.*

*23Malformation Monitoring Centre Saxony-Anhalt, Otto-von-Guericke University, Magdeburg, Germany.*

 *24Brittany Registry of congenital malformations,* Univ Rennes, CHU Rennes, Rennes, France.

*25Registre des Malformations des Antilles (REMALAN), University Hospital of Martinique, Fort-de-France, France.*

*26Congenital Anomaly Register and Information Service for Wales, Public Health Wales, Swansea, United Kingdom.*

*27Center for Human Genetics, Institut de Pathologie et de Génétique, Charleroi, Belgium.*

*28Mainz Model Birth Registry, Center of child and adolescence medicine, University Medical Center Mainz, Germany.*

*29OMNI-Net Ukraine, Khmelnytsky City Children’s Hospital, Khmelnytsky, Ukraine.*

*30European Commission, Joint Research Centre (JRC), Ispra, Italy.*

*31Paediatric Department, Hospital Lillebaelt, Kolding, Denmark.*

Key Words : Congenital cerebral anomalies, Holoprosencephaly, Arhinencephaly, Megalencephaly, Corpus Callosum

*Word Count : 2817*

**Abstract**

**Objectives: To describe the epidemiology and geographical differences in prevalence of congenital cerebral anomalies in Europe.**

**Design and Setting: Congenital cerebral anomalies (ICD10 code Q04) recorded in 29 population-based EUROCAT registries conducting surveillance of 1.7 million births per annum (29% of all European births).**

**Participants: All birth outcomes (livebirths, fetal deaths from 20 weeks gestation and terminations of pregnancy after prenatal diagnosis of a fetal anomaly (TOPFA)) from 2005-2014.**

**Main outcome measures: Prevalence, proportion of associated non-cerebral anomalies, prenatal detection rate.**

**Results: 4927 cases with congenital cerebral anomalies were identified; a prevalence (adjusted for under-reporting) of 9.8 (95% CI: 8.5 to 11.2) per 10,000 births. There was a six-fold difference in prevalence across the registries. Registries with higher proportions of prenatal diagnoses had higher prevalence. Overall, 55% of all cases were liveborn, 3% were fetal deaths and 41% resulted in TOPFA. Forty-eight percent of all cases were an isolated cerebral anomaly, 25% had associated non-cerebral anomalies and 27% were chromosomal or part of a syndrome (genetic or teratogenic). The prevalence excluding genetic or chromosomal conditions increased by 2.4% per annum (95%CI: 1.3% - 3.5%), with the increases occurring only for congenital malformations of the corpus callosum (3.0% per annum) and “other reduction deformities of the brain” (2.8% per annum).**

**Conclusion: Only half of the cases were isolated cerebral anomalies. Improved pre- and postnatal diagnosis may account for the increase in prevalence of congenital cerebral anomalies from 2005 to 2014. However, major differences in prevalence remain between regions.**

**Introduction**

It is important to have background information about the epidemiology of congenital cerebral anomalies including associated anomalies and trends over time. This enables a knowledge-based evaluation of possible future changes in the prevalence and associated anomalies, which could be related to the occurrence of new teratogens. For example, Maternal Zika virus infection is acknowledged to increase the risk of microcephaly occurring in the fetus[1, 2]. However, there is more uncertainty as to the association of maternal Zika virus infections with other structural cerebral anomalies[3].

EUROCAT)is a European network of population-based registries for the epidemiologic surveillance of congenital anomalies ( <http://www.eurocat-network.eu/>) [4, 5]. There are many EUROCAT publications on neural tube defects [6-8], microcephaly [9], hydrocephaly [10] and septo-optic dysplasia [11]. Individual EUROCAT registries have published data on corpus callosum anomalies in Emilia Romagna [12], schizencephaly [13] and holoprosencephaly [14] in the UK. However, the epidemiology of these and other cerebral anomalies from the Q04 chapter in ICD10 such as reduction defects of the brain, microgyria, megalencephaly, cerebral cysts and schizencephaly have never been analysed at a European level and most of these anomalies are quite rare with little published epidemiological data. A previous EUROCAT collaboration with the Surveillance of Cerebral Palsy in Europe network has shown that the majority of congenital anomalies in children with cerebral palsy are cerebral anomalies [15, 16], indicating the severity of the clinical outcome of these congenital anomalies.

Most cerebral anomalies are not recognised at birth, but may be diagnosed pre- and postnatally by ultrasound scans and other imaging examinations including magnetic resonance imaging (MRI). As diagnostic methods, prenatally and in the neonatal period, are known to vary over time, and between countries in Europe, and because some registries include late diagnosed cases up to five years of age or more, major European differences in the prevalence of cerebral anomalies are expected.

The aim of this study was to describe the epidemiology of specific congenital cerebral anomalies in Europe and the observed geographical differences in prevalence using EUROCAT data.

**Methods**

The EUROCAT registries are population based; the geographically defined populations and the methodology of collecting individual case data for EUROCAT is described elsewhere [4]. The registries ascertain congenital anomalies cases from multiple sources, using active case finding and passive notification, such as hospital discharge diagnoses, birth and death certificates and post mortem examinations. Information about livebirths (LB), fetal deaths (FD) with a gestational age (GA) ≥ 20 weeks and terminations of pregnancy after prenatal diagnosis of congenital anomaly (TOPFA) at any gestation is included. All major structural congenital anomalies, syndromes and chromosomal anomalies are included in the database. Minor anomalies are excluded based on a list of ICD10 codes for exclusion (EUROCAT Guide 1.4)[17]. The congenital anomalies have been coded according to ICD10 with the British Paediatric Association (BPA) extension since 2005.

All full member registries were invited to take part in the study and data from 29 EUROCAT registries are included. Data was extracted from the EUROCAT database on 31/05/2017 (Table 1). All birth outcomes (LB, FD and TOPFA) with an ICD10 code within the subchapter Q04 ‘Other congenital malformations of brain’ and born in the years 2005-2014 were included. The anomalies included in Q04 are congenital anomalies of corpus callosum (Q040), arhinencephaly (Q041), holoprosencephaly (Q042), other reduction deformities of brain (Q043), septo-optic dysplasia (Q044), megalencephaly (Q045), congenital cerebral cysts (Q046), other specified anomalies of brain (Q048) and unspecified congenital anomalies of brain (Q049). Some registries added the 4th digit code from British Associations extension of ICD10 for Q043 for further specification (agyria/ lissenencephaly, microgyria/polygyria, hydranencephaly, reduction anomalies of cerebrum, reduction anomalies of cerebellum). A previous paper has reported data from the cases with septo-optic dysplasia [11], which for completeness are also included in this paper. Not all registries contributed data for all 10 years. Data about each case included year of birth, type of birth, GA at birth or termination, infant sex, time of diagnosis, maternal age and associated congenital anomalies.

**Classification of the congenital anomalies**

Cases were classified as isolated cerebral anomalies, chromosomal cases, teratogenic or genetic syndromes or multiple congenital anomalies (anomalies from other organ systems plus a cerebral anomaly) according to the EUROCAT multiple congenital anomaly flowchart [18] and manual review of the written text description of the anomalies. Cases with additional codes and/or written text description of microcephaly, ventriculomegaly and hydrocephaly were classified as isolated cerebral anomalies. Combinations of cerebral anomalies within the Q04 chapter were classified hierarchically according to Table 2 so that all cases were allocated to one main cerebral anomaly diagnosis - diagnoses on the left taking precedence over those on the right. The diagnoses of single cerebral cyst, arachnoid and choroid plexus cysts and anomalies of septum pellucidum are on the EUROCAT list of minor anomalies for exclusion and these cases were therefore excluded, if described in the written text as the only cerebral anomaly. Cases with written text description of large cisterna magna, asymmetric ventricles or minor ventriculomegaly (<15 mm) were excluded if these were the only cerebral anomalies. Colpocephaly was classified as a secondary anomaly if associated with agenesis of corpus callosum. There are no specific ICD10 codes for the most frequent cerebral syndromes (Joubert, Aicardi, Walker-Warburg and Miller-Dieker syndrome) and these are reported based on written text descriptions. There were no written text descriptions for cases from the registries in Paris and Norway and Northern England (NorCAS) used standard written text. Trends over time are presented as pan-European trends excluding genetic cases (chromosomal anomaly or genetic syndrome).

**Method to Identify Under-reporting**

A previous study of septo-optic dysplasia [11] found evidence that some registries were under-reporting cases and developed a method to estimate the prevalence adjusting for this under-reporting. In brief, for each separate anomaly, the average prevalence amongst the 15 registries with the highest prevalence is calculated using a random effects meta-analysis. The average prevalence of the whole population is then estimated by adjusting the prevalence observed in these 15 registries by factors to adjust for the fact that these registries have the highest prevalence estimate amongst 29 registries. These factors depend only on the average number of cases in the registries. The factors are obtained by simulation and calculation of the ratio of the mean prevalence of 15 out of 29 registries compared to the mean prevalence of all 29 registries assuming the number of cases follows a Poisson distribution with an expected value equal to the observed median number of cases in the 15 registries. For example, if only 2 cases are observed in each registry the correction factor is 1.7, whereas if 75 cases are observed the correction factor is only 1.09.

**Statistical Analysis**

The prevalence of the anomalies and the trends over time were investigated by fitting Poisson regression multi-level models with registry as a random effect. Associations between prevalence and prenatal diagnosis rates and the length of follow-up a registry performs (that is up to what age they still collect diagnoses classified into within 1 week, within 1 year and over 1 year) were investigated using Poisson regression with prenatal diagnosis and length of follow-up as covariates. All other exploratory analyses between anomalies were investigated using anova and chi-squared tests according to whether the variable of interest was categorical or not.

**Results**

The study included 4927 cases with a congenital cerebral anomaly giving an overall prevalence (adjusted for under-reporting) of 9.8 (95% CI: 8.5 to 11.2) per 10,000 births in the 29 registries. There were major differences in prevalence by registry (Table 1, Figure 1), with more than a six-fold difference between the registry with the lowest prevalence (South Portugal; 2.7 per 10,000) and the registry with the highest prevalence (French West Indies; 16.6 per 10,000). The proportions of cases that were diagnosed prenatally varied considerably between registries. There was an association between prevalence and the proportion of prenatal diagnoses; registries with higher proportions of prenatal diagnoses had a higher prevalence (p=0.029; Figure 2), but significant heterogeneity between registers still remained. There was no association between length of follow-up performed by the registry and the prevalence (p=0.5).

Congenital malformations of the corpus callosum and “other reduction deformities of the brain” were the most common cerebral anomalies, with an adjusted prevalence of 3.3 (95%CI 2.7 - 3.8) and 2.9 (95%CI 2.5 – 3.4) respectively. The adjusted prevalence of holoprosencephaly was 1.6 (95%CI: 1.4 - 1.8) per 10,000 births and of megalencephaly was 0.08 (95%CI: 0.05 - 0.11) per 10,000 births.

Overall 3448 cases were diagnosed prenatally (70% of the total, ranging from 50% to 94% amongst registries) and of these 2043 resulted in a TOPFA (59% of the prenatally diagnosed cases). The prenatal diagnosis may have occurred due to a different anomaly, we cannot distinguish which anomaly was diagnosed first . Overall 55% of cases were livebirths, 3% fetal deaths and 41% TOPFAs, with large variation between registries and cerebral anomaly. livebirthsPregnancies with septo-optic dysplasia were most likely to result in a live birth (96%) and pregnancies with arhinencephaly least likely to result in a live birth (4%). Overall, 28% of all livebirths were born preterm (GA < 37 weeks) which varied according to anomaly; babies with septo-optic dysplasia and megalencephaly were the least likely to be born preterm (19% and 17% respectively) (Table 2).

The average maternal age for all cases of cerebral anomalies was 29.9 years. The mean maternal age was significantly lower in cases of septo-optic dysplasia (23.4 years).

For all the cases , 48% were isolated cerebral anomalies, 25% were classified as multiple congenital anomalies, 18% had an associated chromosomal anomaly (6% had Patau syndrome) and for 9% a syndrome was diagnosed (Table 3). The most common associated anomalies were congenital heart defects (CHDs; 9%) and septal defects (ASD and VSD) were the most frequent CHDs. Cases with arhinencephaly or holoprosencephaly were more likely to have a chromosomal anomaly (46% and 36% respectively), particularly Patau syndrome (33% and 24% respectively). In contrast, cases with septo-optic dysplasia, megalencephaly or cerebral cysts were more likely to be isolated cerebral anomalies (72%, 71% and 67% respectively). The most common genetic syndromes reported were Joubert syndrome (23 cases) and Aicardi syndrome (13 cases).

Figures 3a-d show that the pan-European prevalence of cases with cerebral anomalies not due to genetic or chromosomal conditions has increased from 2005 to 2014 by 2.4% per annum (94%CI: 1.3% to 3.5%), with the increases occurring for congenital malformations of the corpus callosum by 3.0% (0.8% to 5.3%) and “other reduction deformities of the brain” by 2.8% (0.5% to 5.0%). These significant increases in prevalence remained after adjusting for increases in prenatal diagnoses and for the length of follow-up in the registries

**Discussion**

The overall prevalence (adjusted for under-reporting) of major congenital cerebral anomalies in Europe from 2005-2014 was 9.8 (95%CI: 8.5 – 11.2) per 10,000 births. The prevalence of non-genetic, non-chromosomal anomalies of corpus callosum and of other reduction defects of brain significantly increased, while the prevalences of the other cerebral anomalies were stable. The increases may be due to increased prenatal diagnosis as if cerebral anomalies are not diagnosed prenatally, they may not be diagnosed for several years of age until they emerge in relation to the diagnosis of developmental problems or cerebral palsy[16].

Our adjusted prevalence for corpus callosum anomalies of 3.3 (95%CI: 2.72 – 3.82 ) per 10,000 births with 66% LBs was consistent with two other smaller studies of 38 and 630 cases which did not include fetal losses or TOPFAs [20, 21]. The study from California 1983-2003 [21] showed a prevalence of corpus callosum anomalies 1.8 per 10,000 births and the study from Hungary from 1992-2006 showed a prevalence of 2.05 per 10,000 livebirths [20] . The Californian study found 17% of cases had a chromosomal anomaly similar to the 16% in our study)[21]. The increased risk of preterm birth was also observed in our study [21] .

The adjusted prevalence of holoprosencephaly was 1.6 (95%CI: 1.4 - 1.8) per 10,000 births. A literature review including 21 studies found that the prevalence of holoprosencephaly varied between 0.5 to 1.5 per 10,000 births [22]. The authors concluded that the differences in prevalence were mainly explained by the inclusion criteria (LBs or all pregnancy outcomes including early TOPFA). These studies also found a higher female rate and a high proportion of chromosomal cases as in our study (63% were female and 36% were chromosomal cases).

Our study showed an adjusted prevalence of megalencephaly of 0.08 (95%CI: 0.05 - 0.11) per 10,000 births. To our knowledge, there are no published prevalence figures for this anomaly. Most case series and reports describe megalencephaly as an isolated anomaly [23], which is in line with our findings (71% isolated). A study from a tertiary center in the USA described that almost half of their patients with unilateral megalencephaly had an additional syndrome diagnosis [23]. Tinkle et al [23] report a Japanese study that found 11 of 38 patients (29%) had a syndrome diagnosis (Sasaki et al 2000 – in Japanese so not referenced). In our study, we found a syndrome diagnosis in 16% of cases.

Our study showed an adjusted prevalence of arhinencephaly of 0.04 (95%CI: 0.01 – 0.07) per 10,000 births. The only study we identified reported a prevalence of arhinencephaly of 0.14 (95%CI : 0.06 - 0.25) per 10,000 births in Atlanta [24] and included only 10 cases, while our study included 46 cases.

The prevalence of our remaining three groups (cerebral cysts (Q046), other specified cerebral anomalies (Q048) and unspecified cerebral anomalies (Q049)) is more heterogeneous and therefore difficult to compare with other studies. Cases with congenital cerebral cysts were mainly liveborn (81%), mainly non-genetic (87%) and half of the cases were diagnosed prenatally. Some cases coded Q048 had the written text description “ventriculomegaly”. The EUROCAT definition of hydrocephaly (ICD10 codes in Q03) is a size of the lateral ventricles at 15 mm or more. Cases with an unspecified size of the lateral ventricles or a size at 10-14 mm may have been reported to EUROCAT with the code Q048 for other specified cerebral anomalies. Less than half of the cases reported with unspecified cerebral anomaly were liveborn, indicating the severity of the anomalies but lack of diagnostic details in the EUROCAT registries.

The association between prevalence and prenatal detection rate explains part of the European heterogeneity in the prevalence of cerebral anomalies. In addition, Fetal MRI may be used more frequently in some areas and may increase the detection rate [25]. However, under-ascertainment of cases by the registry may also explain the very low prevalence in some registries. In other registries, there may be over-reporting of minor anomalies seen on cerebral imaging or by reporting cerebral injuries after preterm birth or birth asphyxia using ICD codes from the congenital anomaly chapter. The diagnosis of reduction defect of the cerebellum, often with the written text “small cerebellum” was mainly reported by the English registries and there may be different diagnostic criteria for reporting this anomaly. For some cerebral anomalies, in particular reduction defects, the critical exposure period includes up to gestational week 18 [26]. If ultrasound screening is performed at an earlier GA cases may be missed.

There was a high rate of TOPFAs for the anomalies included in this study indicating the severity of cerebral anomalies. Overall, 41% of all cases were TOPFA with the highest TOPFA rate found for arhinencephaly (91%) and holoprosencephaly (78%). For anomalies of corpus callosum, the TOPFA rate was 31%, possibly due to more severe cerebral anomalies being present. Counselling and parental decision-making after prenatal diagnosis of anomalies of corpus callosum is difficult [27]. A study has shown that 25-30% of fetuses with a prenatal diagnosis of isolated agenesis of corpus callosum have developmental delays [28]. However, a recent study on the use of MR Imaging on fetuses with a suspected brain abnormality on ultrasound showed that fetal MRI changed the prognostic information in 20% of the cases [25].

**Strengths and limitations**

The strength of our study is it is the largest covering 6.4 million births in Europe. All registries use the same inclusion criteria for major anomalies and the same coding and classification system for congenital anomalies. There may be underreporting of cases in some registries, but this is adjusted for in the method for calculating the European prevalence of specific anomalies (which does assume that all populations are at equal risk of occurrence of the congenital anomalies of interest which may not be the case). There may also be some over-reporting of minor anomalies, reporting of diagnosis related to birth complications or misclassification of congenital hydrocephaly as ventriculomegaly.

**Conclusions.**

Our study provides background prevalence information in the time period before the outbreak of the Zika virus . During this period increasing prevalence was reported due to better prenatal detection. Heterogeneity in prevalence between regions of Europe may be explained by differences in the prenatal diagnoses and by underreporting of major anomalies in some registries and reporting of minor anomalies as major in other registries.

**What is already known on this topic**

* Previous studies of structuralcerebral anomalies have often been based on small series of cases rather than population based case series.
* Prevalence of megalencephaly has not been reported

**What this study adds**

* Forty-eight percent of cases with a structural cerebral anomaly were classified as an isolated cerebral anomaly, 25% had associated non-cerebral anomalies and 27% were classified as chromosomal or part of a syndrome (genetic or teratogenic).
* Reported prevalence of congenital cerebral anomalies in Europe increased from 2005 to 2014 with major differences in prevalence between regions and with a significant association between prevalence and prenatal detection rate; improved pre- and postnatal diagnosis may account for this increase.
* The prevalence of megalencephaly was 0.08 (95%CI: 0.05 - 0.11) per 10,000 births

**Competing Interest Statement**

All authors declare: no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

**Transparency declaration**

JKM affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

**Details of Contributors**

EG and JKM conceived the study and cleaned the data in collaboration with the registries. JKM did the statistical analysis and EG wrote the first draft of the article. JR, EG, DW and IB made substantial contributions to classification of the congenital anomalies, interpretation of results and revision of the manuscript. All other co-authors were registry representatives from EUROCAT participating registries. They contributed and validated their data and participated in the interpretation of results and critical revision of the manuscript. JKM is the guarantor. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

**Ethics**

Local procedures regarding ethics approval for the registries’ activities and their collaborations with EUROCAT are available on the EUROCAT website (www.eurocat-network.eu/ABOUTUS/Member-Registries/ MembersAndRegistryDescriptions/AllMembers).

**Data Sharing Statement**

The data used in this study belong to the individual registries. However, requests for case data can be made to the JRC-EUROCAT Central Registry (JRC-EUROCAT@ec.europa.eu) who will ask the individual registries permission to use the data. Aggregate data, updated biannually, are available from the EUROCAT website http://www.eurocat-network.eu/accessprevalencedata/prevalencetables. Data included in the paper was extracted from the EUROCAT database in April 2016.

**Funding**

There was no specific funding for this study. Funding for the JRC-EUROCAT Central Registry is described in “A sustainable solution for the activities of the European network for surveillance of congenital anomalies”[5]. EUROCAT registries are funded as described in: EUROCAT Member Registries: Organization and Processes[4].

Acknowledgements

*We thank JRC-EUROCAT Central Registry,* European Commission, Joint Research Centre (JRC), Ispra, Italy, *for the data management and selection of cases included in the study. We thank the many people throughout Europe involved in providing and processing information, including affected families, clinicians, health professionals, medical record clerks, and registry staff.*

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence (<http://www.bmj.com/sites/default/files/BMJ%20Author%20Licence%20March%202013.doc>) to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution and convert or allow conversion into any format including without limitation audio, iii) create any other derivative work(s) based in whole or part on the on the Contribution, iv) to exploit all subsidiary rights to exploit all subsidiary rights that currently exist or as may exist in the future in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above. All research articles will be made available on an open access basis (with authors being asked to pay an open access fee—see <http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse>). The terms of such open access shall be governed by a [Creative Commons](http://creativecommons.org/) licence—details as to which Creative Commons licence will apply to the research article are set out in our worldwide licence referred to above.

**Table 1**: Number of cases with a congenital cerebral anomaly (ICD10 code Q04),, prevalence and proportion prenatally diagnosed in 29 EUROCAT registries in the period 2005-2014

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Registry, Country  | Years of data | Population births (1000) | Total Cases | Prevalence per 10,000 births | Proportion prenatally diagnosed (%) |
| South Portugal | 2006-2014 | 161 | 44 | 2.7 | 68 |
| South East Ireland | 2005-2014 | 75 | 27 | 3.6 | 59 |
| Zagreb, Croatia | 2005-2014 | 58 | 24 | 4.1 | 71 |
| Wessex, UK | 2005-2014 | 298 | 156 | 5.2 | 86 |
| E Midlands & S Yorkshire, UK | 2005-2012 | 587 | 311 | 5.3 | 83 |
| Tuscany, Italy | 2005-2014 | 300 | 167 | 5.6 | 81 |
| Norway | 2005-2012 | 487 | 273 | 5.6 | 61 |
| Malta | 2005-2014 | 41 | 25 | 6.1 | 36 |
| Cork and Kerry, Ireland | 2005-2014 | 99 | 60 | 6.1 | 48 |
| Hainaut, Belgium | 2005-2014 | 126 | 85 | 6.7 | 72 |
| Emilia Romagna, Italy | 2005-2014 | 400 | 276 | 6.9 | 70 |
| Valencia Region, Spain | 2005-2014 | 403 | 278 | 6.9 | 59 |
| Northern England, UK | 2005-2014 | 331 | 231 | 7.0 | 71 |
| Mainz, Germany | 2005-2014 | 32 | 23 | 7.2 | 78 |
| Ukraine | 2005-2014 | 304 | 219 | 7.2 | 60 |
| Thames Valley, UK | 2005-2014 | 300 | 221 | 7.4 | 77 |
| Northern Netherlands | 2005-2014 | 174 | 130 | 7.5 | 62 |
| Odense, Denmark | 2005-2013 | 41 | 34 | 8.4 | 65 |
| Wales, UK | 2005-2014 | 347 | 305 | 8.8 | 64 |
| Saxony Anhalt, Germany | 2005-2014 | 172 | 153 | 8.9 | 50 |
| Antwerp, Belgium | 2005-2014 | 206 | 185 | 9.0 | 56 |
| Styria, Austria | 2005-2012 | 83 | 77 | 9.3 | 75 |
| Basque Country, Spain | 2007-2014 | 205 | 201 | 9.8 | 77 |
| South West England, UK | 2005-2014 | 496 | 491 | 9.9 | 51 |
| Isle de Reunion, France | 2005-2014 | 146 | 176 | 12.1 | 78 |
| Brittany, France | 2011-2014 | 145 | 182 | 12.5 | 89 |
| Vaud, Switzerland | 2005-2014 | 79 | 122 | 15.4 | 73 |
| Paris, France | 2005-2012 | 214 | 352 | 16.5 | 94 |
| French West Indies, France | 2009-2014 | 60 | 99 | 16.6 | 92 |
|  |  |  |  |  |  |
| Total | 2005-2014 | 6368 | 4927 | 9.78(95%CI: 8.50 - 11.16)1 | 70 |

1 :Total prevalence is adjusted for potential under-reporting (see methods)

 **Table 2:** Epidemiology data for congenital cerebral anomaly cases in29 EUROCAT registries from2005-2014 with cerebral anomaly cases classified according to one main cerebral anomaly category with the diagnoses present on the left taking precedence over the ones on the right

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **ICD 10 Code**  | **Q04.2** | **Q04.1** | **Q04.4** | **Q04.5** | **Q04.3** | **Q04.0** | **Q04.8** | **Q04.6** | **Q04.9** | **Q04** |
| **Anomaly** | Holopros-encephaly | Arhin-encephaly | Septo-optic dysplasia | Megal-encephaly | Other reduction deformities of brain | Congenital malformations of corpus callosum | Other specified congenital malformations of brain | Congenital cerebral cysts | Congenital malformation of brain, unspecified | All Cases |
| **No. of Cases** | 865 | 33 | 94 | 49 | 1,409 | 1,476 | 383 | 375 | 243 | 4927 |
| **No. of diagnoses1** | 865 | 46 | 99 | 49 | 1,464 | 1,748 | 550 | 555 | 273 | 5649 |
| **Prevalence per 10,000 births (95%CI)2** | 1.55(1.37 - 1.77) | 0.04(0.01 - 0.07) | 0.19(0.11 - 0.26) | 0.08(0.05 - 0.11) | 2.92(2.51 - 3.35) | 3.25(2.72 - 3.82) | 0.75(0.53 - 1.01) | 0.69(0.49 - 0.93) | 0.39(0.29 - 0.52) | 9.78(8.5 - 11.16) |
| **Live births No. (%)** | 155 (18) | 2 (6) | 90 (96) | 33 (67) | 792 (56) | 975 (66) | 259 (68) | 302 (81) | 112 (46) | 2720 (55) |
| **Fetal Deaths No. (%)** | 34 (4) | 1 (3) | 0 (0) | 1 (2) | 55 (4) | 37 (3) | 12 (3) | 6 (2) | 18 (7) | 164 (3) |
| **TOPFA No. (%)** | 676 (78) | 30 (91) | 4 (4) | 15 (31) | 562 (40) | 464 (31) | 112 (29) | 67 (18) | 113 (47) | 2043 (41) |
| **Non-genetic No. (%)** | 539 (62) | 12 (36) | 91 (97) | 43 (88) | 1119 (79) | 1156 (78) | 307 (80) | 325 (87) | 192 (79) | 3784 (77) |
| **Average maternal age (years)** | 30 (30 - 31) | 32 (30 - 34) | 23 (22 - 24) | 30 (28 - 32) | 30 (30 - 30) | 30 (30 - 31) | 30 (30 - 31) | 29 (28 - 30) | 29 (29 - 30) | 30 (30-30) |
|  **Preterm birth (GA < 37 weeks) livebirths No. (%)** | 62 (40) | 1 (50) | 17 (19) | 5 (17) | 229 (29) | 208 (22) | 79 (31) | 113 (38) | 34 (32) | 748 (28) |
| **Prenatal Diagnosis No. (%)** | 811 (94) | 32 (97) | 32 (34) | 27 (55) | 962 (68) | 1038 (70) | 207 (54) | 182 (49) | 157 (65) | 3448 (70) |
| **Male No. (%)**  | 316 (37) | 14 (42) | 52 (55) | 29 (59) | 684 (49) | 749 (51) | 198 (52) | 196 (52) | 114 (47) | 2352 (48) |

1: Number of diagnoses will be greater than the number of cases as each case may have more than one different diagnoses of a cerebral anomaly

2 : Adjusted for potential under-reporting (see methods).

**Table 3**: Classification of congenital cerebral anomaly cases according to associated anomalies and genetic diagnosis; 29 EUROCAT registries, 2005-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **ICD 10 Code** | **Q04.2** | **Q04.1** | **Q04.4** | **Q04.5** | **Q04.3** | **Q04.0** | **Q04.8** | **Q04.6** | **Q04.9** | **Q04** |
| **Associated anomalies and genetic diagnoses** **No. (%)** | Holopros-encephaly | Arhin-encephaly | Septo-optic dysplasia | Megal-encephaly | Other reduction deformities of brain | Congenital malform-ations of corpus callosum | Other specified congenital malform-ations of brain | Congenital cerebral cysts | Congenital malformation of brain, unspecified | All Cases |
| **Isolated cerebral anomaly** | 305 (35) | 2 (6) | 68 (72) | 35 (71) | 663 (47) | 764 (52) | 180 (47) | 251 (67) | 112 (46) | 2380 (48) |
| **Chromosomal** | 309 (36) | 21 (46) | 1 (1) | 0 (0) | 203 (14) | 280 (16) | 68 (12) | 43 (8) | 39 (14) | 876 (18) |
| Patau syndrome | 206 (24) | 11 (33) | 0 (0) | 0 (0) | 31 (2) | 24 (2) | 2 (1) | 0 (0) | 11 (5) | 285 (6) |
| Edward’s syndrome | 31 (4) | 1 (3) | 0 (0) | 0 (0) | 50 (4) | 55 (4) | 10 (3) | 24 (6) | 7 (3) | 178 (4) |
| Down’s syndrome | 3 (0) | 0 (0) | 1 (1) | 0 (0) | 23 (2) | 17 (1) | 11 (3) | 1 (0) | 6 (2) | 62 (1) |
| **Genetic syndrome** | 13 (2) | 4 (12) | 1 (1) | 8 (16) | 152 (11) | 92 (6) | 31 (8) | 15 (4) | 13 (5) | 329 (7) |
| **Teratogenic syndromes incl maternal infections**1  | 0 (0) | 0 (0) | 1 (1) | 0 (0) | 34 (2) | 17 (1) | 15 (4) | 9 (2) | 13 (5) | 89 (2) |
| **Multiple congenital anomaly** | 238 (28) | 10 (30) | 23 (24) | 6 (12) | 372 (26) | 364 (25) | 109 (28) | 63 (17) | 68 (28) | 1253 (25) |
|  **with congenital heart defects**  | 68 (8) | 3 (9) | 8 (9) | 1 (2) | 133 (9) | 143 (10) | 40 (10) | 22 (6) | 30 (12) | 448 (9) |
| **with congenital limb anomalies** | 42 (5) | 2 (6) | 4 (4) | 3 (6) | 125 (9) | 94 (6) | 26 (7) | 13 (3) | 17 (7) | 326 (7) |
| **with congenital eye anomalies** | 46 (5) | 2 (6) | 9 (10) | 0 (0) | 21 (1) | 43 (3) | 6 (2) | 8 (2) | 5 (2) | 140 (3) |

1  Underreporting is likely to have occurred

**References**

1. Mysorekar IU, Diamond MS. Modeling Zika Virus Infection in Pregnancy. New England Journal of Medicine. 2016;375(5):481-4. PubMed PMID: 27433842.

2. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika Virus and Birth Defects — Reviewing the Evidence for Causality. New England Journal of Medicine. 2016;374(20):1981-7. doi: 10.1056/NEJMsr1604338. PubMed PMID: 27074377.

3. Melo AS, Aguiar RS, Amorim MM, Arruda MB, Melo FO, Ribeiro ST, et al. Congenital Zika Virus Infection: Beyond Neonatal Microcephaly. JAMA Neurology. 2016;73(12):1407-16. PubMed PMID: 27695855.

4. Boyd PA, Haeusler M, Barisic I, Loane M, Garne E, Dolk H. Paper 1: The EUROCAT network—organization and processes†. Birth Defects Research Part A: Clinical and Molecular Teratology. 2011;91(S1):S2-S15. doi: doi:10.1002/bdra.20780.

5. Kinsner-Ovaskainen A, Lanzoni M, Garne E, Loane M, Morris J, Neville A, et al. A sustainable solution for the activities of the European network for surveillance of congenital anomalies: EUROCAT as part of the EU Platform on Rare Diseases Registration. European Journal of Medical Genetics. 2018;61(9):513-7. doi: 10.1016/j.ejmg.2018.03.008.

6. Khoshnood B, Loane M, de Walle H, Arriola L, Addor MC, Barisic I, et al. Long term trends in prevalence of neural tube defects in Europe: population based study. BMJ. 2015;351:h5949. Epub 2015/11/26. doi: 10.1136/bmj.h5949. PubMed PMID: 26601850; PubMed Central PMCID: PMCPMC4658393.

7. Boyd P, DeVigan C, Khoshnood B, Loane M, Garne E, Dolk H. Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down’s syndrome. BJOG: An International Journal of Obstetrics & Gynaecology. 2008;115(6):689-96. doi: 10.1111/j.1471-0528.2008.01700.x.

8. Busby A, Abramsky L, Dolk H, Armstrong B. Preventing neural tube defects in Europe: population based study. BMJ. 2005;330(7491):574-5. doi: 10.1136/bmj.330.7491.574.

9. Morris JK, Rankin JR, Garne E, Loane M, Greenlees R, Addor MC, et al. Prevalence of Microcephaly in Europe : A Population based study. BMJ. 2016;354:i4721. doi: 10.1136/bmj.i4721.

10. Garne E, Loane M, Addor M-C, Boyd PA, Barisic I, Dolk H. Congenital hydrocephalus: prevalence, prenatal diagnosis and outcome of pregnancy in four European regions. European Journal of Paediatric Neurology. 2010;14(2):150-5. doi: 10.1016/j.ejpn.2009.03.005.

11. Garne E, Rissmann A, Addor M-C, Barisic I, Bergman J, Braz P, et al. Epidemiology of septo-optic dysplasia with focus on prevalence and maternal age – A EUROCAT study. European Journal of Medical Genetics. 2018. doi: 10.1016/j.ejmg.2018.05.010.

12. Ballardini E, Marino P, Maietti E, Astolfi G, Neville AJ. Prevalence and associated factors for agenesis of corpus callosum in Emilia Romagna (1981–2015). European Journal of Medical Genetics. 2018;61(9):524-30. doi: 10.1016/j.ejmg.2018.06.004.

13. Howe D, Rankin J, Draper ES. Schizencephaly prevalence, prenatal diagnosis and clues to etiology: a register‐based study. Ultrasound in Obstetrics & Gynecology. 2012;39(1):75-82. doi: doi:10.1002/uog.9069.

14. Bullen PJ, Rankin JM, Robson SC. Investigation of the epidemiology and prenatal diagnosis of holoprosencephaly in the North of England. American Journal of Obstetrics & Gynecology. 2001;184(6):1256-62. doi: 10.1067/mob.2001.111071.

15. Garne E, Dolk H, Krägeloh-Mann I, Holst Ravn S, Cans C. Cerebral palsy and congenital malformations. European Journal of Paediatric Neurology. 2008;12(2):82-8. doi: 10.1016/j.ejpn.2007.07.001.

16. Rankin J, Cans C, Garne E, Colver A, Dolk H, Uldall P, et al. Congenital anomalies in children with cerebral palsy: a population‐based record linkage study. Developmental Medicine & Child Neurology. 2010;52(4):345-51. doi: 10.1111/j.1469-8749.2009.03415.x.

17. EUROCAT Guide 1.4 [14/02/2018]. Available from: <http://www.eurocat-network.eu/aboutus/datacollection/guidelinesforregistration/guide1_4>.

18. Garne E, Dolk H, Loane M, Wellesley D, Barisic I, Calzolari E, et al. Paper 5: Surveillance of multiple congenital anomalies: Implementation of a computer algorithm in European registers for classification of cases. Birth Defects Research Part A: Clinical and Molecular Teratology. 2011;91(S1):S44-S50. doi: doi:10.1002/bdra.20777.

19. Riley EP. Abnormalities of the corpus callosum in children prenatally exposed to alcohol. Alcoholism: Clinical & Experimental Research. 1995;19(5).

20. Szabó N, Gergev G, Kóbor J, Bereg E, Túri S, Sztriha L. Corpus Callosum Anomalies: Birth Prevalence and Clinical Spectrum in Hungary. Pediatric Neurology. 2011;44(6):420-6. doi: 10.1016/j.pediatrneurol.2011.01.002.

21. Glass HC. Agenesis of the corpus callosum in California 1983-2003: a population-based study. American journal of medical genetics Part A. 2008;146A(19).

22. Orioli IM, Castilla EE. Epidemiology of holoprosencephaly: Prevalence and risk factors. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2010;154C(1):13-21. doi: 10.1002/ajmg.c.30233.

23. Tinkle BT, Schorry EK, Franz DN, Crone KR, Saal HM. Epidemiology of hemimegalencephaly: A case series and review. American Journal of Medical Genetics Part A. 2005;139A(3):204-11. doi: 10.1002/ajmg.a.31024.

24. Rasmussen SA, Moore CA, Khoury MJ, Cordero JF. Descriptive epidemiology of holoprosencephaly and arhinencephaly in metropolitan Atlanta, 1968-1992. American journal of medical genetics. 1996;66(3):320-33. Epub 1996/12/18. doi: 10.1002/(sici)1096-8628(19961218)66:3<320::aid-ajmg16>3.0.co;2-o. PubMed PMID: 8985495.

25. Griffiths PD, Bradburn M, Campbell MJ, Cooper CL, Graham R, Jarvis D, et al. Use of MRI in the diagnosis of fetal brain abnormalities in utero (MERIDIAN): a multicentre, prospective cohort study. The Lancet. 2017;389(10068):538-46. doi: 10.1016/S0140-6736(16)31723-8.

26. Czeizel AE. Specified critical period of different congenital abnormalities: A new approach for human teratological studies. Congenital Anomalies. 2008;48(3):103-9. doi: 10.1111/j.1741-4520.2008.00189.x.

27. Santo S, D'Antonio F, Homfray T, Rich P, Pilu G, Bhide A, et al. Counseling in fetal medicine: agenesis of the corpus callosum. Ultrasound in Obstetrics & Gynecology. 2012;40(5):513-21. doi: doi:10.1002/uog.12315.

28. Sotiriadis A, Makrydimas G. Neurodevelopment after prenatal diagnosis of isolated agenesis of the corpus callosum: an integrative review. American Journal of Obstetrics & Gynecology. 2012;206(4):337.e1-.e5. doi: 10.1016/j.ajog.2011.12.024.